Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 1201 • 2019 ACR/ARP Annual Meeting
Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?
Claire Barber¹, Natalie Shiff ², Cheryl Barnabe ³, Susanne Benseler ³, Ricky Chin ³, Nicole Johnson ³, Nadia Luca ³, Paivi Miettunen ⁴, Marinka Twilt ³, Dwaraka Veeramreddy ³ and Heinrike Schmeling ⁵, ¹University of Calgary, Calgary, Canada, ²University of Florida, Gainesville, FL, ³University of Calgary, Calgary, AB, Canada, ⁴Alberta Children's Hospital, Calgary, ON, Canada, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Wait time to pediatric rheumatology care for patients with Juvenile Idiopathic Arthritis (JIA) is a nationally endorsed quality measure in Canada. Target wait times…
Abstract Number: 2706 • 2019 ACR/ARP Annual Meeting
Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry
Agna Neto¹, Ana Filipa Mourão ², Filipa Oliveira-Ramos ³, Raquel Marques ³, Paula Estanqueiro ⁴, Manuel Salgado ⁴, Margarida Guedes ⁵, Daniela Piotto ⁶, Clovis Artur Silva ⁷, José Melo Gomes ⁸, Marta Cabral ⁹, Marta Conde ¹⁰, Ricardo Figueira ¹¹, Maria José Santos ¹², João Eurico Fonseca ¹³, Maria Teresa Terreri ⁶ and Helena Canhão ¹⁴, ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon; Hospital Central do Funchal, Madeira., Lisbon, Portugal, ²Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal, ³Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Lisbon, Portugal, ⁴Pediatrics, Hospital Pediátrico Carmona da Mota, Coimbra, Coimbra, Portugal, ⁵Unidade de Imunologia Clínica, Centro Hospitalar Universitário do Porto, Porto, Portugal, ⁶Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Universidade de São Paulo, São Paulo, Brazil, ⁸Instituto Português de Reumatologia; Clínica Dr. Melo Gomes, Lisbon., Lisbon, Portugal, ⁹Pediatrics, Hospital Prof. Doutor Fernando Fonseca, Lisbon, Lisbon, Portugal, ¹⁰Pediatric Rheumatology Unit, Hospital Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Lisbon, Portugal, ¹¹Rheumatology Department, Hospital Central do Funchal, Funchal, Madeira, Portugal, ¹²Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ¹⁴CEDOC, EpiDoC Unit, NOVA Medical School, Lisbon, Lisbon, Portugal
Background/Purpose: In adults with Rheumatoid Arthritis, obesity has been associated with higher disease activity. However, in Juvenile Idiopathic Arthritis (JIA), the influence of body mass…
Abstract Number: 188 • 2019 ACR/ARP Annual Meeting
The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood
Kristin Wipfler¹, Sofia Pedro ¹, Yomei Shaw ¹, Rebecca Schumacher ¹, Teresa Simon ², Alyssa Dominique ³, Adam Reinhardt ⁴ and Kaleb Michaud ⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb*, Princeton, NJ, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Children’s Hospital & Medical Center & University of Nebraska Medical Center, Omaha, NE, ⁵FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Upon transitioning from pediatric to adult care, many patients with JIA are labeled as having RA, despite the two diagnoses being distinct in care…
Abstract Number: 1814 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era
Gabriella Giancane¹, Valentina Muratore ², Valentina Marzetti ³, Neus Quilis ³, Belen Serrano Benavente ³, Francesca Bagnasco ³, Alessandra Alongi ⁴, Adele Civino ⁵, Alessandro Consolaro ⁶ and Angelo Ravelli ⁷, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, ²IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy, ³IRCCS Gaslini, Genoa, ⁴Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, ⁵Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, ⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ⁷IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy
Background/Purpose: After nearly two decades from the start of the Biologic era, systematic analyses of patients with juvenile idiopathic arthritis (JIA) have shown a high…
Abstract Number: 2710 • 2019 ACR/ARP Annual Meeting
Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
Fabrizio De Benedetti¹, Inmaculada Calvo Penadés ², Nadina Rubio-Pérez ³, Alexey Maschan ⁴, Pierre Quartier ⁵, Zbigniew Żuber ⁶, Marina Stanislav ⁷, Raul Barria ⁸, Daniel Clemente ⁹, Gabriel Vega-Cornejo ¹⁰, Nancy Liu ¹¹, Christine Xu ¹¹, Angeliki Giannelou ¹², Bolanle Akinlade ¹² and Lydie Baret-Cormel ¹³, ¹Bambino Gesù Children’s Hospital, Rome, Italy, ²Hospital Univ. La Fe, Valencia, Spain, ³University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ⁴Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, ⁵Necker Hospital, Paris, France, ⁶Andrzej Frycz Modrzewski Krakow University, Kraków, Poland, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸Bioreuma, Concepción, Chile, ⁹Hospital Infantil Universitario Niño Jesús, Madrid, Spain, ¹⁰CREA de Guadalajara, Jalisco, Mexico, ¹¹Sanofi, Bridgewater, NJ, ¹²Regeneron, New York, NY, ¹³Sanofi, Chilly-Mazarin, France
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to membrane and soluble IL-6 receptor-α. Sarilumab is approved for adults with rheumatoid arthritis (RA) and is being…
Abstract Number: 255 • 2019 ACR/ARP Annual Meeting
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
Esi Morgan¹, Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ², Anne Paul ², Catherine Bingham ⁴, Danielle Bullock ⁵, Kerry Ferraro ⁶, Y Goh ⁷, Mileka Gilbert ⁸, Olha Halyabar ⁹, Karla Jones ¹⁰, Melanie Kohlheim ¹¹, Daniel J. Lovell ¹², Darby MacDonald ¹⁰, Emily Smitherman ¹³, Anjie Vago ¹⁴, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹⁰, Angela Young ¹⁶, Michelle Batthish ¹⁷, Beth Gottlieb ¹⁸, Julia Harris ¹⁹, Melissa Hazen ²⁰, Ronald Laxer ⁷, Tzielan Lee ²¹, Melissa Mannion ²², Judyann Olson ²³, MIchael Shishov ²⁴, Sheetal Vora ²⁵ and Jonathan Burnham ²⁶, ¹Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Penn State Hershey Children's, Hershey, ⁵University of Minnesota, Minneapolis, MN, ⁶PR-CON Parent Working Group, Fort Washington, PA, ⁷Hospital for Sick Children, Toronto, ON, Canada, ⁸Medical Univeristy of South Carolina, Charleston, SC, ⁹Boston Children's Hospital, Boston, ¹⁰Nationwide Children's Hospital, Columbus, OH, ¹¹PR-COIN Parent Working Group, Columbus, OH, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴PR-COIN Parent Working Group, Hershey, PA, ¹⁵Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁶PR-COIN Parent Working Group, Lexington, KY, ¹⁷McMaster University, Hamilton, Canada, ¹⁸Cohen Children's Hospital, New Hyde Park, NY, ¹⁹Children's Mercy Hospital, Kansas City, MO, ²⁰Boston Children's Hospital, Boston, MA, ²¹Stanford University School of Medicine, Palo Alto, ²²Children's of Alabama, Birmingham, ²³Medical College of WIsconsin, Milwaukee, WI, ²⁴Phoenix Children's, Phoenix, AZ, ²⁵Levine Children's, Charlotte, NC, ²⁶The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In 2018 an international task force published a recommended Treat to Target (T2T) approach to juvenile idiopathic arthritis (JIA) treatment. In February 2019, 17…
Abstract Number: 1817 • 2019 ACR/ARP Annual Meeting
Arthropathy of Down Syndrome: An Under-diagnosed Inflammatory Joint Disease That Warrants a Name Change
Charlene Foley¹, Derek Deely ², Emma Jane MacDermott ² and Orla Killeen ², ¹Great Ormond Street Hospital, London, Ireland, ²National Centre for Paediatric Rheumatology (NCPR), Our Lady's Children's Hospital Crumlin (OLCHC), Dublin, Ireland
Background/Purpose: Incidence and prevalence of arthropathy of Down syndrome (A-DS) is increased. It is rarely recognised at onset and remains under-diagnosed. Children with A-DS are therefore…
Abstract Number: 2711 • 2019 ACR/ARP Annual Meeting
Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Daniah Basodan¹, Kathleen M Andersen ², Xintong Li ³, Jeffrey Curtis ⁴ and G. Caleb Alexander ⁵, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD
Background/Purpose: In recent years, juvenile idiopathic arthritis (JIA) treatment options have expanded to include biologics such as tumor necrosis factor inhibitors (TNFi) and non-TNF inhibitors…
Abstract Number: 773 • 2019 ACR/ARP Annual Meeting
Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation
Megan Simonds ¹, Amanda Schlefman ¹, Suzanne McCahan ¹, Kathleen Sullivan ², Carlos Rose ³ and AnneMarie Brescia³, ¹Nemours Biomedical Research, Wilmington, DE, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Nemours/ Alfred I DuPont Hospital for Children, Wilmington, DE
Background/Purpose: Progression of Juvenile Idiopathic Arthritis (JIA) can lead to growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a key role in the pathogenesis…
Abstract Number: 1883 • 2019 ACR/ARP Annual Meeting
Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients
Jaymin Upadhyay¹, Diana Sibai ¹, Robert Labadie ², Jordan Lemme ³, Christine Sieberg ², Kirsten Ecklund ⁴, David Borsook ⁴ and Robert Sundel ⁴, ¹Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Boston Children’s Hospital, Harvard Medical School, Boston, MA, ³Boston Children's Hospital, Harvard Medical School, Boston, ⁴Boston Children’s Hospital, Harvard Medical School, Boston
Background/Purpose: Despite a broad range of available therapeutics, pain remains poorly treated in many juvenile idiopathic arthritis (JIA) patients1-2. For some patients, the level of pain…
Abstract Number: 2712 • 2019 ACR/ARP Annual Meeting
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Natalie Shiff¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Yukiko Kimura ⁴, Dax Rumsey ⁵, Jennifer Schenfeld ⁶, Scott Stryker ³, Marinka Twilt ⁷ and Timothy Beukelman ⁸, ¹University of Florida, Gainesville, FL, ²Duke University, Durham, NC, ³Amgen Inc., Thousand Oaks, CA, ⁴Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Amgen, Inc, Thousand Oaks, CA, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
Abstract Number: 779 • 2019 ACR/ARP Annual Meeting
The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants
Kaiyu Jiang ¹, Yungki Park ¹, Tarbell Evan ¹, Tao Liu ² and James N. Jarvis³, ¹University at Buffalo Jacobs School of Medicine, Buffalo, NY, ²Roswell Park Cancer Instiyute, Buffalo, NY, ³University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY
Background/Purpose: IL2RA has been identified as a JIA-associated risk locus using both candidate gene and genetic fine mapping approaches. However, numerous gene expression studies comparing…
Abstract Number: 1920 • 2019 ACR/ARP Annual Meeting
School Nurse Education for Juvenile Idiopathic Arthritis
W. Blaine Lapin¹, Carleigh Kutac ², Danielle Guttman-Lapin ³, Amanda Brown ², Eyal Muscal ² and Filiz Seeborg ², ¹Baylor College of Medicine, Connecticut Children's Medical Center, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Aldine Independent School District, Houston, TX
Background/Purpose: There is a paucity of literature on the challenges children with JIA face at school. Despite treatment advances, children with JIA often rate their…
Abstract Number: 2714 • 2019 ACR/ARP Annual Meeting
Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry
Melissa Mannion¹, Fenglong Xie ² and Timothy Beukelman ³, ¹University of Alabama at Birmingham, Alabama, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Inactive disease is the stated goal of treatment in juvenile idiopathic arthritis (JIA) and is typically measured by a composite score that combines several…
Abstract Number: 781 • 2019 ACR/ARP Annual Meeting
Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?
Charlene Foley¹, Achilleas Floudas ², Sharon Ansboro ², Mary Canavan ², Monika Biniecka ², Emma Jane MacDermott ³, Ronan Mullan ⁴, Gerry Wilson ⁵, Ursula Fearon ⁶ and Orla Killeen ⁷, ¹Great Ormond Street Hospital, London, Ireland, ²TBSI, Dublin, Ireland, ³OLCHC, Dublin, Ireland, ⁴Tallaght Hospital, Dublin, Ireland, ⁵UCD, Dublin, Ireland, ⁶TBSI, Dublin, ⁷National Centre for Paediatric Rheumatology (NCPR), Our Lady’s Children’s Hospital Crumlin (OLCHC), Dublin, Ireland
Background/Purpose: Down syndrome associated Arthritis (DA) is 20 times more common than JIA. It is an erosive, polyarticular RF negative arthritis with predominance in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].